All In Biotech

Drug Trial Radar · NCT07898072

Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism

A Single-Blind, Single-Arm, Multiple-Dose Study Evaluating the Safety and Efficacy of Testosterone Cypionate Administered Subcutaneously Via a Weekly Auto-Injector in Adult Males With Hypogonadism Through Week 24

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Mar 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Amneal Pharmaceuticals, LLCIndustry
Sponsor type
Industry
Collaborators
Avant Sante Research Center S.A. de C.V.
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 3 clinical trial is to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism. The main questions it aims to answer are: * Does weekly testosterone cypionate administered using an auto-injector maintain testosterone levels within the normal range in adult males with hypogonadism? * What side effects and safety outcomes occur during treatment with testosterone cypionate auto-injector? * Is the auto-injector easy for participants to use and self-administer? All participants will receive testosterone cypionate administered subcutaneously once weekly through an auto-injector. Treatment will begin at a 75 mg weekly dose, with dose adjustments to 50 mg or 100 mg based on testosterone levels measured during the study. Participants will: * Receive weekly testosterone cypionate injections using an auto-injector for up to 52 weeks. * Attend regular clinic visits for physical examinations, laboratory tests, blood pressure monitoring, and safety assessments. * Provide blood samples to measure testosterone and other hormone levels and evaluate pharmacokinetics. * Complete questionnaires related to symptoms, quality of life, and ease of use of the auto-injector. * Record self-administration and treatment compliance in a study diary. This study will enroll adult males aged 18 to 75 years with hypogonadism and low testosterone concentrations to evaluate treatment through Week 24, with continued safety follow-up through Week 52.

Conditions

  • Male Hypogonadism

Interventions

  • Testosterone Cypionate 75 mgDrug

    Testosterone cypionate injectable solution formulated in cottonseed oil, supplied in a single-use auto-injector containing 75 mg/0.5 mL. The study drug will be administered subcutaneously into the abdomen once weekly. All participants will initiate treatment at 75 mg once weekly, with dose adjustments in 25 mg increments to 50 mg or 100 mg based on serum total testosterone trough concentrations according to protocol-defined criteria. Treatment will continue through the 24-week primary evaluation period, with eligible participants permitted to continue once-weekly treatment through Week 52 for extended safety assessment.

  • Testosterone cypionate 50 mgDrug

    Testosterone cypionate injectable solution formulated in cottonseed oil, supplied in a single-use auto-injector containing 50 mg/0.5 mL. The study drug will be administered subcutaneously into the abdomen once weekly. All participants will initiate treatment at 75 mg once weekly, with dose adjustments in 25 mg increments to 50 mg or 100 mg based on serum total testosterone trough concentrations according to protocol-defined criteria. Treatment will continue through the 24-week primary evaluation period, with eligible participants permitted to continue once-weekly treatment through Week 52 for extended safety assessment.

  • Testosterone cypionate 100 mgDrug

    Testosterone cypionate injectable solution formulated in cottonseed oil, supplied in a single-use auto-injector containing 100 mg/0.5 mL. The study drug will be administered subcutaneously into the abdomen once weekly. All participants will initiate treatment at 75 mg once weekly, with dose adjustments in 25 mg increments to 50 mg or 100 mg based on serum total testosterone trough concentrations according to protocol-defined criteria. Treatment will continue through the 24-week primary evaluation period, with eligible participants permitted to continue once-weekly treatment through Week 52 for extended safety assessment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Average Serum Total Testosterone Concentration Within 300-1100 ng/dL at Week 12Time frame: Week 12 (over the 168-hour dosing interval following the Week 12 dose)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of California (UCLA) (Site ID 111)

    Santa Monica, California · Not yet recruiting

  • Accel Research Site Alcanza Clinical Research (Site ID 103)

    DeLand, Florida · Not yet recruiting

  • Floridian Clinical Research LLC (Site ID 101)

    Miami Lakes, Florida · Recruiting

  • Quality Research Center (Site ID 104)

    Omaha, Nebraska · Recruiting

  • AccuMed Research Associates (Site ID 106)

    Garden City, New York · Recruiting

  • Integrated Medical Professionals/Advanced Urology Centers of New York (Site ID 107)

    New York, New York · Not yet recruiting

  • Brown University (Site ID 108)

    Providence, Rhode Island · Not yet recruiting

  • Coastal Carolina Research Center (Site ID 102)

    North Charleston, South Carolina · Not yet recruiting

  • Biobehavioral Research Center of Austin (Austin TX) (Site ID 105)

    Austin, Texas · Recruiting

  • Baylor College of Medicine (Site ID 109)

    Houston, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.